This inventor holds 1 USPTO granted patent. Top assignee: Quest Pharmatech, Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations of Prakash Radhakrishnan
Introduction
Prakash Radhakrishnan is an accomplished inventor based in Omaha, NE (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies.
Latest Patents
Radhakrishnan holds a patent for the MUC16 monoclonal antibody and its uses. This patent describes an antibody or an antigen-binding fragment that binds to the O-glycan mucin-type glycoprotein MUC16. The invention includes three variable heavy domain complementarity determining regions (CDR H1, H2, and H3), and three variable light domain CDR (CDR L1, L2, and L3). Additionally, the patent relates to pharmaceutical compositions, nucleic acid vectors, and methods for inhibiting tumor growth of tumors expressing the MUC16 glycoprotein.
Career Highlights
Radhakrishnan is currently associated with Quest Pharmatech, Inc., where he continues to advance his research and development efforts. His work has the potential to impact cancer treatment significantly.
Collaborations
Some of his notable coworkers include Ragupathy Madiyalakan and Michael Hollingsworth, who contribute to the innovative environment at Quest Pharmatech.
Conclusion
Prakash Radhakrishnan's work in developing the MUC16 monoclonal antibody showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his innovative spirit continues to inspire others in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile